Lucira Health, Inc.
$0.45+0.00%(+$0.00)
TickerSpark Score
63/100
100
Valuation
25
Profitability
55
Growth
84
Health
50
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LHDX research report →
52-Week Range8% of range
Low $0.11
Current $0.45
High $4.35
Companywww.lucirahealth.com
Lucira Health, Inc. , a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services.
- CEO
- Erik T. Engelson
- IPO
- 2021
- Employees
- 221
- HQ
- EmeryVille, CA, US
Price Chart
-89.99% · this period
Valuation
- Market Cap
- $18.36M
- P/E
- -0.24
- P/S
- 0.20
- P/B
- 0.08
- EV/EBITDA
- 1.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 10.99%
- Op Margin
- -69.36%
- Net Margin
- -69.67%
- ROE
- -102.50%
- ROIC
- -33.68%
Growth & Income
- Revenue
- $93.06M · 34492.94%
- Net Income
- $-64,827,000 · -73.33%
- EPS
- $-1.86 · -78.85%
- Op Income
- $-64,540,000
- FCF YoY
- -126.49%
Performance & Tape
- 52W High
- $4.35
- 52W Low
- $0.11
- 50D MA
- $0.36
- 200D MA
- $1.20
- Beta
- 3.76
- Avg Volume
- 21.45M
Get TickerSpark's AI analysis on LHDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 3, 23 | Engelson Erik T. | other | 574,666 |
| Mar 3, 23 | Engelson Erik T. | sell | 574,666 |
| Mar 3, 23 | Engelson Erik T. | sell | 60,000 |
| Mar 3, 23 | Engelson Erik T. | other | 574,666 |
| Mar 3, 23 | Narido Richard Clavano | sell | 10,674 |
| Mar 3, 23 | Narido Richard Clavano | sell | 9,675 |
| Mar 3, 23 | Narido Richard Clavano | sell | 4,742 |
| Mar 6, 23 | Narido Richard Clavano | sell | 1,910 |
| Mar 7, 23 | Narido Richard Clavano | sell | 2,382 |
| Mar 3, 23 | Collins Kevin Walter | sell | 30,102 |
Our LHDX Coverage
We haven't published any research on LHDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LHDX Report →